Phase II Study of Pembrolizumab and Itacitinib for Patients with Metastatic NSCLC Expressing PD-L1: Long-Term Follow up

被引：0
|
作者：
Marmarelis, M. E. [1 ]
Cantor, D. J. [1 ]
Mathew, D. [1 ]
McWilliams, T. [1 ]
Bauml, J. [2 ]
Hwang, W-T [1 ]
Singh, A. [1 ]
D'Avella, C. [1 ]
Davis, C. [1 ]
Ye, D. [1 ]
Sun, L. [1 ]
Ciunci, C. [1 ]
Aggarwal, C. [1 ]
Cohen, R. B. [1 ]
Minn, A. [1 ]
Wherry, J. [1 ]
Langer, C. J. [1 ]
机构：
[1] Univ Penn, Philadelphia, PA USA
[2] Janssen, Philadelphia, PA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Immunotherapy; JAK; Pembrolizumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA06.04
引用
收藏
页码：S20 / S20
页数：1
相关论文
共 50 条
  • [1] Phase II Study of Pembrolizumab and Itacitinib for First Line Treatment of Metastatic NSCLC Expressing PD-L1
    Marmarelis, M. E.
    Mathew, D.
    Bauml, J. M.
    Hwang, W. -T.
    Zhang, J.
    Singh, A.
    D'Avella, C.
    Davis, C.
    Ye, D.
    Sun, L.
    Ciunci, C.
    Zhang, N.
    Aggarwal, C.
    Cohen, R. B.
    Minn, A. J.
    Wherry, E. J.
    Langer, C. J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S122 - S123
  • [2] Long time follow-up data of first-line pembrolizumab for advanced NSCLC patients with PD-L1 TPS of 50% or greater
    Tambo, Yuichi
    Sone, Takashi
    Shibata, Kazuhiko
    Nishi, Kouichi
    Shirasaki, Hiroki
    Yoneda, Taro
    Araya, Tomoyuki
    Kase, Kazumasa
    Nishikawa, Shingo
    Kimura, Hideharu
    Kasahara, Kazuo
    ANNALS OF ONCOLOGY, 2021, 32 : S313 - S313
  • [3] Long-term real- world outcomes of first-line (1L) pembrolizumab (pembro) monotherapy in PD-L1 ≥50% metastatic NSCLC.
    Velcheti, Vamsidhar
    Hu, Xiaohan
    Piperdi, Bilal
    Yang, Lingfeng
    Burke, Thomas A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Long-term follow-up of anti-PD-1 naive patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
    Lorentzen, Cathrine Lund
    Kjeldsen, Julie Westerlin
    Ehrnrooth, Eva
    Andersen, Mads Hald
    Svane, Inge Marie
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (05)
  • [5] Immune correlates and long-term follow-up of a Phase Ia study of MPDL3280A, an engineered PD-L1 antibody, in patients with metastatic renal cell carcinoma (mRCC)
    McDermott, David F.
    Kluger, Harriet M.
    Sosman, Jeffrey A.
    Infante, Jeffrey R.
    Soria, Jean-Charles
    Hamid, Omid
    Delord, Jean-Pierre
    Fasso, Marcella
    Wang, Yan V.
    Bruey, Jean-Marie
    Fine, Gregg D.
    Powles, Thomas
    BJU INTERNATIONAL, 2014, 114 : 12 - 12
  • [6] Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in "PD-L1 Negative" NSCLC
    Perrone, Fabiana
    Leonetti, Alessandro
    Tiseo, Marcello
    Facchinetti, Francesco
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (08) : 1128 - 1132
  • [7] The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with high PD-L1 expressing advanced NSCLC tumors
    Schakenraad, Alexandra
    Hashemi, Sayed
    Twisk, Jos
    Houda, Ilias
    Ulas, Ezgi
    Daniels, Johannes M. A.
    Veltman, Joris
    Bahce, I.
    LUNG CANCER, 2021, 162 : 36 - 41
  • [8] Macrophages are important source of PD-L1 and PD-L1 expressing in macrophages affect the prognosis of NSCLC patients with tumor PD-L1 negative
    Liu, Y.
    Cao, L.
    Che, X.
    Qiu, X.
    Li, Z.
    Yang, B.
    Wang, S.
    Qu, X.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 531 - 532
  • [9] Extrinsic Upregulation of PD-L1 Induced by Pembrolizumab Combination Therapy in Patients with NSCLC with Low Tumor PD-L1 Expression
    Kunimasa, Kei
    Nakamura, Harumi
    Nishino, Kazumi
    Nakatsuka, Shin-ichi
    Kumagai, Toru
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : E231 - E233
  • [10] Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC
    Takeyasu, Yuki
    Yoshida, Tatsuya
    Shibaki, Ryota
    Matsumoto, Yuji
    Goto, Yasushi
    Kanda, Shintaro
    Horinouchi, Hidehito
    Yamamoto, Noboru
    Motoi, Noriko
    Ohe, Yuichiro
    CLINICAL LUNG CANCER, 2021, 22 (02) : 127 - +
12345